CYP19A1 and breast carcinoma: Anti-estrogen therapy with estrogen antagonists or aromatase inhibitors is standard first-line treatment for ERα-positive breast cancers, but has been associated with only a low rate (~10%) of overall response among endometrial cancers13, 16, 17, 18 and is not a standard treatment for endometrial cancer3, 4.